Sugi Predict

Sugi Predict / Compounds / SCHEMBL5473174

SCHEMBL5473174

SCHEMBL5473174

O=C(O)c1ccc2[nH]c(-c3nc4cscc4[nH]c3=O)cc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSNK2A1 P68400 4/20 0.40
▸ ITK Q08881 1/20 0.40
▸ CASP3 P42574 1/20 0.39
▸ SENP8 Q96LD8 1/20 0.39
▸ SENP7 Q9BQF6 1/20 0.39
▸ SENP6 Q9GZR1 1/20 0.39
▸ PARP1 P09874 4/20 0.38
▸ CSNK2A2 P19784 1/20 0.38
▸ CSNK2B P67870 1/20 0.38
▸ HRH3 Q9Y5N1 1/20 0.38
▸ GRIK1 P39086 2/20 0.37
▸ GRIK2 Q13002 1/20 0.37
▸ GRIK3 Q13003 1/20 0.37
▸ HSP90AA1 P07900 1/20 0.36
▸ ESR2 Q92731 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ MGLL Q99685 1/20 0.36
▸ KDR P35968 3/20 0.35
▸ KDM4E B2RXH2 3/20 0.35
▸ SRPK1 Q96SB4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14508726 0.91 ITK (0.50) CSNK2A1ITKCASP3SENP8SENP7
SCHEMBL14508639 0.85 ITK (0.44) ITKKDRKDM4EALDH1A1HPGD
SCHEMBL14508598 0.84 KDR (0.48) PARP1MGLLKDRHPGDNPC1
SCHEMBL5957992 0.83 RAB9A (0.52) ITKCASP3SENP8SENP7SENP6
SCHEMBL14508659 0.83 VCP (0.38) ITKKDRKDM4EALDH1A1HPGD
SCHEMBL14508597 0.83 KDR (0.48) PARP1HRH3MGLLKDRHPGD
SCHEMBL14508745 0.83 KDM4E (0.42) PARP1ESR2TDP1KDRKDM4E
SCHEMBL14508655 0.83 ITK (0.52) ITKKDM4ERECQLALDH1A1HPGD
SCHEMBL14508824 0.82 KDR (0.47) PARP1MGLLKDRALDH1A1HPGD
SCHEMBL14508675 0.81 DAO (0.47) ITKTDP1KDRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070105851-A1 Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis BAYER PHARMACEUTICALS CORPORATION (US) 2007-05-10 — — US disclosed
US-20070105851-A1 Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis BAYER PHARMACEUTICALS CORPORATION (US) 2007-05-10 — — US disclosed
US-20070105851-A1 Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis BAYER PHARMACEUTICALS CORPORATION (US) 2007-05-10 — — US disclosed
EP-1687313-A1 INDOLYL-THIEN 3,4-B]PYRAZIN-3-ONE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS Bayer Pharmaceuticals Corporation (US) 2006-08-09 — — EP disclosed
WO-2005051957-A1 INDOLYL-THIENO`3,4-B!PYRAZIN-3-ONE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS BAYER PHARMACEUTICALS CORPORATION (US) 2005-06-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105851-A1 Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis MKI67, CDK4, PGF CSNK2A1 1311/4885ITK 1485/4885CASP3 2618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.